Last reviewed · How we verify
M-M-RVAXPRO
M-M-RVAXPRO is a Live attenuated viral vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of measles, mumps, and rubella in children and adults. Also known as: Measles, mumps and rubella vaccine (live).
M-M-RVAXPRO is a live attenuated combination vaccine that stimulates immune response against measles, mumps, and rubella viruses.
M-M-RVAXPRO is a live attenuated combination vaccine that stimulates immune response against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable. -
Big-pharma sponsor
+3.0pp
Sanofi Pasteur, a Sanofi Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | M-M-RVAXPRO |
|---|---|
| Also known as | Measles, mumps and rubella vaccine (live) |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Live attenuated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that trigger the body's adaptive immune system to produce antibodies and cellular immunity against these three viral pathogens. Upon vaccination, the attenuated viruses replicate minimally in the host, sufficient to generate protective immunity without causing disease. This provides long-term protection against natural infection with wild-type measles, mumps, and rubella viruses.
Approved indications
- Prevention of measles, mumps, and rubella in children and adults
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Rash
- Parotitis (mumps-related)
- Arthralgia/arthritis (rubella-related)
Key clinical trials
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M-M-RVAXPRO CI brief — competitive landscape report
- M-M-RVAXPRO updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about M-M-RVAXPRO
What is M-M-RVAXPRO?
How does M-M-RVAXPRO work?
What is M-M-RVAXPRO used for?
Who makes M-M-RVAXPRO?
Is M-M-RVAXPRO also known as anything else?
What drug class is M-M-RVAXPRO in?
What development phase is M-M-RVAXPRO in?
What are the side effects of M-M-RVAXPRO?
Related
- Drug class: All Live attenuated viral vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of measles, mumps, and rubella in children and adults
- Also known as: Measles, mumps and rubella vaccine (live)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing